Jump to content

XBiotech: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Line 19: Line 19:
| website = {{URL|xbiotech.com}}
| website = {{URL|xbiotech.com}}
}}
}}
'''XBiotech Inc.''' is an clinical-stage [[biopharmaceutical]] company based in [[Austin, Texas]].<ref name="auto">{{Cite web|url=https://www.statesman.com/story/news/2016/11/17/how-austins-xbiotech-aims-to-revolutionize-drug-discovery/10175950007/|title=How Austin's XBiotech aims to revolutionize drug discovery|first=Lilly|last=Rockwell|website=Austin American-Statesman}}</ref><ref name="auto4">{{Cite web|url=https://www.bloomberg.com/quote/XBIT:US|title=XBIT: XBiotech Inc Stock Price Quote - NASDAQ GS - Bloomberg|website=Bloomberg.com}}</ref> It specializes in the [[research and development]] of human-derived antibody therapeutics for multiple diseases, including [[cancer]], [[rheumatological]], and [[infectious disease]]s.<ref name="auto4"/>
'''XBiotech Inc.''' is an clinical-stage [[biopharmaceutical]] company based in [[Austin, Texas]].<ref name="auto">{{Cite web|url=https://www.statesman.com/story/news/2016/11/17/how-austins-xbiotech-aims-to-revolutionize-drug-discovery/10175950007/|title=How Austin's XBiotech aims to revolutionize drug discovery|first=Lilly|last=Rockwell|website=[[Austin American-Statesman]]}}</ref><ref name="auto4">{{Cite web|url=https://www.bloomberg.com/quote/XBIT:US|title=XBIT: XBiotech Inc Stock Price Quote - NASDAQ GS - Bloomberg|website=Bloomberg.com}}</ref> It specializes in the [[research and development]] of human-derived antibody therapeutics for multiple diseases, including [[cancer]], [[rheumatological]], and [[infectious disease]]s.<ref name="auto4"/>


==History==
==History==
XBiotech was founded in 2005 in [[Vancouver]], [[Canada]] by John Simard.<ref name="auto"/><ref>https://www.bizjournals.com/austin/print-edition/2014/10/17/meet-john-simard-ceo-of-xbiotech.html</ref> The company moved its headquarters to [[Austin, Texas]] in 2008.<ref name="auto"/>
XBiotech was founded in 2005 in [[Vancouver]], [[Canada]] by John Simard.<ref name="auto"/><ref>https://www.bizjournals.com/austin/print-edition/2014/10/17/meet-john-simard-ceo-of-xbiotech.html</ref> The company moved its headquarters to [[Austin, Texas]] in 2008.<ref name="auto"/>


In September 2016, XBiotech was listed on [[Nasdaq]], raising $70.9 million through its [[initial public offering]] (IPO).<ref name="auto5">{{Cite web|url=https://www.statesman.com/story/business/2016/09/24/xbiotech-prices-austins-first-ipo-of-2015/10037783007/|title=XBiotech prices Austin’s first IPO of 2015|first=Dan|last=Zehr|website=Austin American-Statesman}}</ref><ref>{{Cite web|url=https://www.statesman.com/story/business/2016/09/24/shares-of-austin-based-xbiotech-soar-on-first-trading-day/10108419007/|title=Shares of Austin-based XBiotech soar on first trading day|first=Lori|last=Hawkins|website=Austin American-Statesman}}</ref> The company allocated about $42 million of the proceeds to complete later-stage trials for one of its key cancer drugs and to construct a new manufacturing and research facility in southeast Austin.<ref name="auto5"/> The remaining funds were used for earlier-stage trials of other products and general corporate purposes.<ref name="auto5"/> In March 2017, XBiotech announced a registered direct offering in which it sold over $30 million of its common shares at a price of $13 per share.<ref name="auto2">{{Cite web|url=https://www.statesman.com/story/news/2017/03/03/austins-xbiotech-aims-to-raise-31-million-with-offering/10172560007/|title=Austin's XBiotech aims to raise $31 million with offering|first=Bob|last=Sechler|website=Austin American-Statesman}}</ref> In the same year, XBiotech opened a 40,000-square-foot production facility in Southeast Austin.<ref>https://www.bizjournals.com/austin/news/2016/09/27/xbiotechs-road-to-revenue-runs-through-gleaming.html</ref>
In September 2016, XBiotech was listed on [[Nasdaq]], raising $70.9 million through its [[initial public offering]] (IPO).<ref name="auto5">{{Cite web|url=https://www.statesman.com/story/business/2016/09/24/xbiotech-prices-austins-first-ipo-of-2015/10037783007/|title=XBiotech prices Austin’s first IPO of 2015|first=Dan|last=Zehr|website=[[Austin American-Statesman]]}}</ref><ref>{{Cite web|url=https://www.statesman.com/story/business/2016/09/24/shares-of-austin-based-xbiotech-soar-on-first-trading-day/10108419007/|title=Shares of Austin-based XBiotech soar on first trading day|first=Lori|last=Hawkins|website=[[Austin American-Statesman]]}}</ref> The company allocated about $42 million of the proceeds to complete later-stage trials for one of its key cancer drugs and to construct a new manufacturing and research facility in southeast Austin.<ref name="auto5"/> The remaining funds were used for earlier-stage trials of other products and general corporate purposes.<ref name="auto5"/> In March 2017, XBiotech announced a registered direct offering in which it sold over $30 million of its common shares at a price of $13 per share.<ref name="auto2">{{Cite web|url=https://www.statesman.com/story/news/2017/03/03/austins-xbiotech-aims-to-raise-31-million-with-offering/10172560007/|title=Austin's XBiotech aims to raise $31 million with offering|first=Bob|last=Sechler|website=[[Austin American-Statesman]]}}</ref> In the same year, XBiotech opened a 40,000-square-foot production facility in Southeast Austin.<ref>https://www.bizjournals.com/austin/news/2016/09/27/xbiotechs-road-to-revenue-runs-through-gleaming.html</ref>


In October 2017, XBiotech enrolled its first patient in a clinical study to evaluate the effectiveness of its antibody MABp1 in combination with ONIVYDE and 5-fluorouracil/folinic acid for treating [[pancreatic cancer]].<ref>https://www.reuters.com/article/brief-xbiotech-enrolls-first-patient-in-idUSFWN1MT0O7/</ref>
In October 2017, XBiotech enrolled its first patient in a clinical study to evaluate the effectiveness of its antibody MABp1 in combination with ONIVYDE and 5-fluorouracil/folinic acid for treating [[pancreatic cancer]].<ref>https://www.reuters.com/article/brief-xbiotech-enrolls-first-patient-in-idUSFWN1MT0O7/</ref>

Revision as of 16:16, 4 October 2024

XBiotech
Company typePublic
Nasdaq: XBIT
IndustryBiopharmaceutical
Founded2005 (2005) in Canada
FounderJohn Simard
Headquarters
Austin, Texas
,
United States
Area served
Worldwide
Key people
John Simard (CEO)
Websitexbiotech.com

XBiotech Inc. is an clinical-stage biopharmaceutical company based in Austin, Texas.[1][2] It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases.[2]

History

XBiotech was founded in 2005 in Vancouver, Canada by John Simard.[1][3] The company moved its headquarters to Austin, Texas in 2008.[1]

In September 2016, XBiotech was listed on Nasdaq, raising $70.9 million through its initial public offering (IPO).[4][5] The company allocated about $42 million of the proceeds to complete later-stage trials for one of its key cancer drugs and to construct a new manufacturing and research facility in southeast Austin.[4] The remaining funds were used for earlier-stage trials of other products and general corporate purposes.[4] In March 2017, XBiotech announced a registered direct offering in which it sold over $30 million of its common shares at a price of $13 per share.[6] In the same year, XBiotech opened a 40,000-square-foot production facility in Southeast Austin.[7]

In October 2017, XBiotech enrolled its first patient in a clinical study to evaluate the effectiveness of its antibody MABp1 in combination with ONIVYDE and 5-fluorouracil/folinic acid for treating pancreatic cancer.[8]

In December 2019, XBiotech's drug for dermatological conditions, Bermekimab, was acquired by Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, for $750 million.[9][10] XBiotech is eligible for up to $600 million in milestone payments, potentially increasing the total value of the deal to $1.35 billion.[9]

During the COVID-19 pandemic, XBiotech worked with BioBridge Global to offer its antibody screening technology to the South Texas Blood & Tissue Center.[11] The technology identified patients with natural antibodies effective against the virus.[11] XBiotech also developed a COVID-19 therapy candidate by isolating specific antibodies and their genes from convalescent plasma, aiming to create a mass-producible, purified antibody product.[11]

Xilonix

XBiotech is known for developing Xilonix, a candidate therapeutic for treating advanced colorectal cancer by targeting tumor-associated inflammation, an approach intended to inhibit both tumor growth and metastasis.[6]

Xilonix received fast-track designation from the United States Food and Drug Administration in 2012 and had progressed to Phase 3 trials in both the United States and Europe by 2016.[4][12] In February 2017, XBiotech reported in an SEC filing that it had received an extension from European regulators to address deficiencies the agency was asserting in the registration application.[6] The company indicated it expected to meet the new deadline of March 22 to respond to these issues.[6]

References

  1. ^ a b c Rockwell, Lilly. "How Austin's XBiotech aims to revolutionize drug discovery". Austin American-Statesman.
  2. ^ a b "XBIT: XBiotech Inc Stock Price Quote - NASDAQ GS - Bloomberg". Bloomberg.com.
  3. ^ https://www.bizjournals.com/austin/print-edition/2014/10/17/meet-john-simard-ceo-of-xbiotech.html
  4. ^ a b c d Zehr, Dan. "XBiotech prices Austin's first IPO of 2015". Austin American-Statesman.
  5. ^ Hawkins, Lori. "Shares of Austin-based XBiotech soar on first trading day". Austin American-Statesman.
  6. ^ a b c d Sechler, Bob. "Austin's XBiotech aims to raise $31 million with offering". Austin American-Statesman.
  7. ^ https://www.bizjournals.com/austin/news/2016/09/27/xbiotechs-road-to-revenue-runs-through-gleaming.html
  8. ^ https://www.reuters.com/article/brief-xbiotech-enrolls-first-patient-in-idUSFWN1MT0O7/
  9. ^ a b https://www.bizjournals.com/austin/news/2020/02/10/1-35b-deal-offers-vindication-runway-for-austin.html
  10. ^ https://www.bizjournals.com/austin/news/2019/12/31/xbiotech-sells-new-drug-candidate-in-750m-deal.html
  11. ^ a b c https://www.bizjournals.com/austin/news/2020/08/27/xbiotech-dell-medical-school-convalescent-plasma.html
  12. ^ Hawkins, Lori. "Austin-based XBiotech files for an IPO". Austin American-Statesman.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=XBiotech&oldid=1249377527"